HLA-B
Basic information
Region (hg38): 6:31353872-31367067
Previous symbols: [ "AS" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Drug-induced toxicity, susceptibility to | AD | Pharmacogenomic | Susceptibility to adverse reactions (including Stevens-Johnson syndrome), may have pharmacogenomic importance related to a number of medications, including abacavir, allopurinol, carbamazepine, flucocloxacillin | General | 3477129; 16415921; 16538176; 17258541; 19933789; 203459391; 21244392; 21428768; 21676164; 22348415; 22348435 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HLA-B gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | 11 | ||||
missense | 9 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 8 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 0 | 18 | 10 |
Variants in HLA-B
This is a list of pathogenic ClinVar variants found in the HLA-B region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-31354498-C-A | Likely benign (Apr 11, 2018) | |||
6-31355138-G-A | Benign (Jun 18, 2018) | |||
6-31355144-A-G | Likely benign (Jul 01, 2022) | |||
6-31355224-C-G | not provided (-) | |||
6-31355378-C-T | Likely benign (Aug 01, 2024) | |||
6-31355490-C-T | EBV-positive nodal T- and NK-cell lymphoma | Pathogenic (-) | ||
6-31355564-G-A | Likely benign (Nov 01, 2022) | |||
6-31356164-T-A | not provided (-) | |||
6-31356245-TCC-T | HLA-B-related disorder | Benign (Dec 17, 2020) | ||
6-31356248-G-T | Likely benign (May 01, 2024) | |||
6-31356248-G-GTC | HLA-B-related disorder | Benign (Dec 17, 2020) | ||
6-31356297-C-T | Likely benign (Jan 01, 2024) | |||
6-31356367-T-G | HLA-B-related disorder | Benign (Dec 17, 2020) | ||
6-31356389-G-A | Benign (Jul 01, 2024) | |||
6-31356418-T-A | Likely benign (Jul 01, 2023) | |||
6-31356418-T-G | Likely benign (Jun 01, 2024) | |||
6-31356423-G-C | HLA-B-related disorder | Benign (Dec 17, 2020) | ||
6-31356686-AC-GA | not provided (-) | |||
6-31356687-C-T | not provided (-) | |||
6-31356712-C-A | HLA-B-related disorder | Likely benign (Dec 17, 2020) | ||
6-31356711-C-CGG | HLA-B-related disorder | Likely benign (Dec 17, 2020) | ||
6-31356713-G-C | Likely benign (Jul 01, 2024) | |||
6-31356716-C-A | Likely benign (May 01, 2023) | |||
6-31356716-C-G | Likely benign (May 01, 2023) | |||
6-31356716-CA-C | HLA-B-related disorder | Likely benign (Dec 17, 2020) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HLA-B | protein_coding | protein_coding | ENST00000412585 | 7 | 3317 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0000386 | 0.957 | 27804 | 62749 | 35194 | 125747 | 0.530 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.0112 | 196 | 196 | 1.00 | 0.00000977 | 2123 |
Missense in Polyphen | 110 | 130.87 | 0.84052 | 1447 | ||
Synonymous | 0.131 | 77 | 78.5 | 0.981 | 0.00000423 | 660 |
Loss of Function | 1.85 | 10 | 18.6 | 0.538 | 8.04e-7 | 194 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 2.21 | 1.59 |
Ashkenazi Jewish | 1.34 | 0.650 |
East Asian | 0.861 | 0.520 |
Finnish | 1.02 | 0.483 |
European (Non-Finnish) | 1.17 | 0.496 |
Middle Eastern | 0.861 | 0.520 |
South Asian | 1.27 | 0.604 |
Other | 1.16 | 0.515 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the presentation of foreign antigens to the immune system.;
- Pathway
- Antigen processing and presentation - Homo sapiens (human);Cell adhesion molecules (CAMs) - Homo sapiens (human);Type I diabetes mellitus - Homo sapiens (human);Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human);Allograft rejection - Homo sapiens (human);Graft-versus-host disease - Homo sapiens (human);Viral myocarditis - Homo sapiens (human);Endocytosis - Homo sapiens (human);Autoimmune thyroid disease - Homo sapiens (human);Phagosome - Homo sapiens (human);HTLV-I infection - Homo sapiens (human);Natural killer cell mediated cytotoxicity - Homo sapiens (human);Viral carcinogenesis - Homo sapiens (human);Cellular senescence - Homo sapiens (human);Epstein-Barr virus infection - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);Abacavir Pathway, Pharmacokinetics/Pharmacodynamics;Proteasome Degradation;Allograft Rejection;Type II interferon signaling (IFNG);Neutrophil degranulation;DAP12 interactions;Cytokine Signaling in Immune system;Innate Immune System;Immune System;Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell;Adaptive Immune System;Endosomal/Vacuolar pathway;Antigen processing-Cross presentation;Class I MHC mediated antigen processing & presentation;Interferon gamma signaling;Interferon alpha/beta signaling;Antigen Presentation: Folding, assembly and peptide loading of class I MHC;Interferon Signaling
(Consensus)
Intolerance Scores
- loftool
- 0.996
- rvis_EVS
- 8.95
- rvis_percentile_EVS
- 99.96
Haploinsufficiency Scores
- pHI
- hipred
- N
- hipred_score
- 0.328
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.447
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | High | High | High |
Primary Immunodeficiency | High | High | High |
Cancer | High | High | High |
Gene ontology
- Biological process
- positive regulation of T cell mediated cytotoxicity;antigen processing and presentation of peptide antigen via MHC class I;antigen processing and presentation of endogenous peptide antigen via MHC class Ib;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent;antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent;immune response;regulation of immune response;interferon-gamma-mediated signaling pathway;type I interferon signaling pathway
- Cellular component
- Golgi membrane;extracellular space;endoplasmic reticulum;Golgi apparatus;plasma membrane;external side of plasma membrane;cell surface;ER to Golgi transport vesicle membrane;phagocytic vesicle membrane;early endosome membrane;MHC class I protein complex;recycling endosome membrane;integral component of lumenal side of endoplasmic reticulum membrane
- Molecular function
- signaling receptor binding;protein binding;peptide antigen binding